Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults

A Gamma Variant RBD-based aluminum hydroxide adjuvanted vaccine called ARVAC CG was selected for a first in human clinical trial. Healthy male and female participants (18-55 years old) with a complete COVID-19-primary vaccine scheme were assigned to receive two intramuscular doses of either a low-do...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasquevich, Karina A., Coria, Lorena M., Ceballos, Ana, Mazzitelli, Bianca, Rodriguez, Juan Manuel, Demaría, Agostina, Pueblas Castro, Celeste, Bruno, Laura, Saposnik, Lucas, Salvatori, Melina, Varese, Augusto, González, Soledad, González Martínez, Veronica V., Geffner, Jorge, Álvarez, Diego, Feleder, Ethel, Halabe, Karina, Perez Lera, Pablo E., de Oca, Federico Montes, Vega, Julio C., Lombardo, Mónica, Yerino, Gustavo A., Fló, Juan, Cassataro, Juliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382514/
https://www.ncbi.nlm.nih.gov/pubmed/37507392
http://dx.doi.org/10.1038/s41467-023-40272-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382514/
https://www.ncbi.nlm.nih.gov/pubmed/37507392
http://dx.doi.org/10.1038/s41467-023-40272-3

Ejemplares similares